Impact of ruxolitinib pretreatment on outcomes after allogeneic stem cell transplantation in patients with myelofibrosis.

Sharifah Shahnaz Syed Abd KadirMaximilian ChristopeitGerald WulfEva WagnerMartin BornhauserThomas SchroederMartina CrysandtKarin MayerJulia JonasMatthias StelljesAnita BadbaranFrancis Ayuketang AyukIoanna TriviaiDominik WolfChristine WolschkeNicolaus Kröger

Published in: European journal of haematology (2018)

These results suggest that ruxolitinib pretreatment in myelofibrosis patient does not negatively influence outcome after allogeneic stem cell transplantation.

Keyphrases

stem cell transplantation
high dose
case report
low dose